Key Events This Week
May 11: Stock opens at Rs.517.10, down 2.54% amid broad market weakness
May 12: Continued decline to Rs.504.05 (-2.52%) as Sensex falls sharply
May 13: Stabilisation at Rs.503.90 (-0.03%) with Sensex modestly up
May 14: Further dip to Rs.498.40 (-1.09%) despite Sensex gains
May 15: Sharp rally to Rs.575.60 (+15.49%) following mixed quarterly results
May 11–14: Early Week Declines Amid Market Downturn
The week began with Shree Ganesh Remedies opening at Rs.517.10 on 11 May, a 2.54% decline from the previous Friday’s close of Rs.530.60. This drop coincided with a broad market sell-off as the Sensex fell 1.40% to 35,679.54. The downward trend continued on 12 May, with the stock slipping further by 2.52% to Rs.504.05, mirroring the Sensex’s sharper 2.19% decline to 34,899.09.
On 13 May, the stock price stabilised at Rs.503.90, down a marginal 0.03%, while the Sensex rebounded slightly by 0.32% to 35,010.26. Despite this, the stock failed to gain momentum and declined again on 14 May by 1.09% to Rs.498.40, even as the Sensex advanced 1.01% to 35,364.44. These early week movements reflected cautious investor sentiment amid sector and market uncertainties.
May 15: Sharp Rebound on Mixed Quarterly Results
The final trading day of the week saw a dramatic turnaround as Shree Ganesh Remedies surged 15.49% to close at Rs.575.60 on heavy volume of 47,476 shares, a significant increase compared to earlier days. This rally occurred despite the Sensex falling 0.36% to 35,236.50, underscoring the stock’s strong relative performance.
The price jump followed the release of the company’s quarterly results for March 2026, which presented a complex financial picture. Shree Ganesh Remedies reported record net sales of ₹33.20 crores and its highest-ever PBDIT of ₹11.38 crores, signalling robust operational performance. The company also achieved a peak PBT excluding other income at ₹7.70 crores, indicating strong core profitability.
However, the net profit after tax contracted by 22.06% to ₹9.36 crores for the half-year, reflecting margin pressures and increased costs. The Return on Capital Employed (ROCE) declined to 14.23%, and the Debtors Turnover Ratio fell to 3.36 times, highlighting challenges in capital efficiency and working capital management. These mixed signals contributed to the stock’s volatility but did not deter the sharp price appreciation on the day of results.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Quarterly Results: Operational Strength Amid Profitability Pressures
Shree Ganesh Remedies’ quarterly report revealed a nuanced financial performance. The company’s net sales reached a record ₹33.20 crores, reflecting strong demand within the Pharmaceuticals & Biotechnology sector. Operating profits also peaked, with PBDIT at ₹11.38 crores and PBT excluding other income at ₹7.70 crores, indicating improved operational leverage and margin expansion.
Despite these positives, net profit after tax declined by 22.06% to ₹9.36 crores for the half-year, signalling margin compression and higher expenses. The ROCE dropped to 14.23%, suggesting deteriorating capital efficiency. Additionally, the Debtors Turnover Ratio fell to 3.36 times, the lowest in recent periods, pointing to slower receivables collection and potential liquidity concerns.
The company’s financial trend score shifted from flat to negative, though it improved slightly from -22 to -5 over three months. The Mojo Grade was upgraded from Strong Sell to Sell as of 12 January 2026, with a current Mojo Score of 37.0, reflecting cautious optimism amid operational challenges.
Considering Shree Ganesh Remedies Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Comparative Weekly Price Performance
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-11 | Rs.517.10 | -2.54% | 35,679.54 | -1.40% |
| 2026-05-12 | Rs.504.05 | -2.52% | 34,899.09 | -2.19% |
| 2026-05-13 | Rs.503.90 | -0.03% | 35,010.26 | +0.32% |
| 2026-05-14 | Rs.498.40 | -1.09% | 35,364.44 | +1.01% |
| 2026-05-15 | Rs.575.60 | +15.49% | 35,236.50 | -0.36% |
Key Takeaways
Positive Signals: The company’s record net sales and peak operating profits demonstrate strong underlying business momentum. The sharp price rally on 15 May reflects investor recognition of operational strength despite broader market weakness. The upgrade in Mojo Grade from Strong Sell to Sell indicates a modest improvement in outlook.
Cautionary Signals: The 22.06% decline in net profit after tax and the drop in ROCE to 14.23% highlight margin pressures and deteriorating capital efficiency. The slowdown in Debtors Turnover Ratio to 3.36 times raises concerns about working capital management and liquidity. The stock’s volatility and wide 52-week trading range suggest ongoing uncertainty.
Overall, the week encapsulated a complex narrative of operational highs tempered by profitability and efficiency challenges, resulting in a volatile but ultimately positive price outcome.
Conclusion
Shree Ganesh Remedies Ltd’s week was defined by a significant rebound in share price following the release of mixed quarterly results. While the company achieved record sales and operating profits, the contraction in net profit and weakening efficiency ratios underscore ongoing challenges. The stock’s 8.48% weekly gain, contrasting with the Sensex’s 2.63% decline, highlights its relative strength amid market volatility.
Investors should remain attentive to the company’s ability to stabilise margins and improve capital utilisation in forthcoming quarters. The mixed signals from the latest results suggest a cautious stance, balancing the operational progress against profitability pressures and working capital concerns. The stock’s performance this week reflects both the opportunities and risks inherent in Shree Ganesh Remedies’ current financial trajectory.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
